NCT01880385 - Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

September 30, 2013

Study Completion Date

April 30, 2017

Conditions

Inflammatory Breast Cancer

Interventions

BIOLOGICAL

Bevacizumab

During neoadjuvant phase: 15 mg/kg, d1 q3w, 4 cycles

DRUG

Cyclophosphamide

Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles

DRUG

epirubicin hydrochloride

Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles

DRUG

fluorouracil

Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles

DRUG

Docetaxel

Adjuvant: 100 mg/m2 q3w, 4 cycles

BIOLOGICAL

Trastuzumab

Adjuvant: 8 mg/kg d1 in the 1st cycle then 6 mg/kg for d1 q3w, 17 cycles if tumor overexpress HER2

Trial Locations (1)

RECRUITING

Institut Salah Azaiz, Bab Saadoun